Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anemia
Levels of a hematopoiesis inhibitor partially explain anemia in heart failure
November 18th, 2005
According to research from the Netherlands, levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) partially explain the occurrence of anemia in heart failure. "Anemia is common in patients with chronic heart failure (CHF) and is associated with a poor prognosis. However, only a minority of patients with CHF have impaired renal function or underlying hematinic deficiencies," wrote P. van der Meer and colleagues, University Medical Center Groningen. "It has been shown that inhibition of the renin-angiotensin system is associated with the development of anemia. The aim of the present study was to determine possible mechanisms...
Source: Drug Week (2005-11-18)
|
